A study of antibody response to Covid-19 infection

Swapnil R. Jain, Ashish Diwan, Ravendra Singh, A. Julka
{"title":"A study of antibody response to Covid-19 infection","authors":"Swapnil R. Jain, Ashish Diwan, Ravendra Singh, A. Julka","doi":"10.18231/j.ijirm.2023.005","DOIUrl":null,"url":null,"abstract":": The Coronavirus disease 2019 is a disease caused by the etiological agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was a newly identified β-coronavirus that had spread rapidly around the world, resulting in a very high number of infections and deaths, threatening public security, and placing a heavy burden on global healthcare systems and economy. The present study was done to study antibody response in COVID-19 infection.: The study was carried out in the Department of Respiratory Medicine, R.D. Gardi Medical College, Ujjain, India after approval by ethics committee. The post COVID-19 cases attending respiratory medicine OPD were included in the study.: The present study was conducted in 122 patients. The mean age of the patients was 51.20±14.21 years, median age was 54.5 years, the minimum age was 14 years and the maximum age was 80 years, the most number of COVID-19 infection cases was in the elderly age group of more than 50 years. The severity of disease was seen in those above 50 years of age (57.3%) with p>0.05. Among the severe cases mean age of the cases was 49±17 years, in moderate cases mean age 52±14 and among mild group of cases mean age was 51±15 years.In the present study there were 73.8% males and females were 26.2% Among COVID-19 cases who reported in the OPD the maximum that is 86 (>70%) patients had moderately severe disease, while severe cases were only about 14 %. Mild cases were 15.6%.In the present study RT-PCR were negative in 36(29.5%) as against 86 (70.5%) were confirmed cases of COVID-19 and among positive cases 40 % cases became negative between 6-10 daysAmong severe disease cases mean SARS COV2 antibody 650.06±240.47 was significantly higher as compare to moderate cases 461.49±331.41 and mild cases 404.11±240.47.: India has the world’s largest vaccination program. COVID-19 antibodies estimation are important tests carried out to determine the response of the body against COVID-19 infection.Our results show a significant association between SARS COV2 antibody and the severity of disease.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"11 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IP Indian Journal of Immunology and Respiratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.ijirm.2023.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

: The Coronavirus disease 2019 is a disease caused by the etiological agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was a newly identified β-coronavirus that had spread rapidly around the world, resulting in a very high number of infections and deaths, threatening public security, and placing a heavy burden on global healthcare systems and economy. The present study was done to study antibody response in COVID-19 infection.: The study was carried out in the Department of Respiratory Medicine, R.D. Gardi Medical College, Ujjain, India after approval by ethics committee. The post COVID-19 cases attending respiratory medicine OPD were included in the study.: The present study was conducted in 122 patients. The mean age of the patients was 51.20±14.21 years, median age was 54.5 years, the minimum age was 14 years and the maximum age was 80 years, the most number of COVID-19 infection cases was in the elderly age group of more than 50 years. The severity of disease was seen in those above 50 years of age (57.3%) with p>0.05. Among the severe cases mean age of the cases was 49±17 years, in moderate cases mean age 52±14 and among mild group of cases mean age was 51±15 years.In the present study there were 73.8% males and females were 26.2% Among COVID-19 cases who reported in the OPD the maximum that is 86 (>70%) patients had moderately severe disease, while severe cases were only about 14 %. Mild cases were 15.6%.In the present study RT-PCR were negative in 36(29.5%) as against 86 (70.5%) were confirmed cases of COVID-19 and among positive cases 40 % cases became negative between 6-10 daysAmong severe disease cases mean SARS COV2 antibody 650.06±240.47 was significantly higher as compare to moderate cases 461.49±331.41 and mild cases 404.11±240.47.: India has the world’s largest vaccination program. COVID-19 antibodies estimation are important tests carried out to determine the response of the body against COVID-19 infection.Our results show a significant association between SARS COV2 antibody and the severity of disease.
新型冠状病毒感染抗体反应的研究
2019冠状病毒病是由病原体严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)引起的疾病。这是一种新发现的β-冠状病毒,在世界范围内迅速传播,导致大量感染和死亡,威胁公共安全,给全球卫生保健系统和经济带来沉重负担。本研究旨在研究COVID-19感染的抗体反应。本研究经伦理委员会批准后,在印度乌贾因R.D. Gardi医学院呼吸内科进行。本研究纳入了在呼吸内科门诊就诊的COVID-19后病例。本研究共纳入122例患者。患者平均年龄为51.20±14.21岁,中位年龄为54.5岁,最小年龄为14岁,最大年龄为80岁,50岁以上老年人感染病例最多。病情严重程度以50岁以上者居多(57.3%),p>0.05。重症组患者平均年龄49±17岁,中度组患者平均年龄52±14岁,轻度组患者平均年龄51±15岁。本组病例中,男性占73.8%,女性占26.2%。在门诊报告的COVID-19病例中,最多86例(>70%)为中重度病例,重症病例仅占14%左右。轻症占15.6%。在本研究中,确诊病例86例(70.5%),RT-PCR阴性36例(29.5%),阳性病例在6-10 d内变为阴性的占40%。重症病例平均COV2抗体(650.06±240.47)明显高于中度病例(461.49±331.41)和轻度病例(404.11±240.47)。印度拥有世界上最大的疫苗接种计划。COVID-19抗体评估是确定身体对COVID-19感染反应的重要测试。我们的研究结果显示,SARS COV2抗体与疾病严重程度之间存在显著关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信